Progress in understanding adjuvant immunotoxicity mechanisms

被引:101
作者
Batista-Duharte, Alexander [1 ]
Lindblad, Erik B. [2 ]
Oviedo-Orta, Ernesto [3 ]
机构
[1] Med Sci Univ, Toxicol & Biomed Ctr TOXIMED, Immunotoxicol Lab, Santiago De Cuba 90400, Cuba
[2] EAAC, DK-3600 Frederikssund, Denmark
[3] Univ Surrey, Fac Hlth & Med Sci, Guildford GU2 5XH, Surrey, England
关键词
Adjuvants; Vaccine; Side effects; Immunotoxicity; IMMUNE-STIMULATING COMPLEXES; HEAT-SHOCK PROTEINS; INFLUENZA VACCINE; ACTIVATE CASPASE-1; POSTERIOR PARESIS; INDUCED ARTHRITIS; FREUNDS-ADJUVANT; NATURAL-KILLER; LEAK SYNDROME; BELLS-PALSY;
D O I
10.1016/j.toxlet.2011.03.001
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Over the last twenty years research has provided an important insight into the mechanisms responsible for the immunotoxicity of both local and systemic adverse reactions following the use of immunostimulating drugs and adjuvants. In this article we provide an update of the present knowledge relating to the various parameters and reactants of the immune system at the cellular as well as molecular level that are believed to play a key role in reactogenicity. We discuss evidence obtained from observations in vitro, in vivo in animal models and from clinical applications, including adjuvants used in large scale vaccination today. The data discussed are mainly taken from animal models following hyperstimulation of the immune system; either by the use of very powerful adjuvants, like Freund's that are too toxic for use in practical vaccination, by deliberate high dose application of adjuvants or by the in vivo application of cytokines. Although such hyperstimulating regimens are unlikely to find their way into practical vaccination of humans, this information is of great value as it may facilitate the understanding of the toxicity mechanisms, aid the design of standardised models for the assessment of adjuvant safety and the possible application of new adjuvants in vaccines for humans. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 101 条
[1]  
Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111
[2]   A1(OH)3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background [J].
Authier, FJ ;
Sauvat, S ;
Christov, C ;
Chariot, P ;
Raisbeck, G ;
Poron, MF ;
Yiou, F ;
Gherardi, R .
NEUROMUSCULAR DISORDERS, 2006, 16 (05) :347-352
[3]   Central nervous system disease in patients with macrophagic myofasciitis [J].
Authier, FJ ;
Cherin, P ;
Creange, A ;
Bonnotte, B ;
Ferrer, X ;
Abdelmoumni, A ;
Ranoux, D ;
Pelletier, J ;
Figarella-Branger, D ;
Granel, B ;
Maisonobe, T ;
Coquet, M ;
Degos, JD ;
Gherardi, RK .
BRAIN, 2001, 124 :974-983
[4]   Vascular leak syndrome: a side effect of immunotherapy [J].
Baluna, R ;
Vitetta, ES .
IMMUNOPHARMACOLOGY, 1997, 37 (2-3) :117-132
[5]   Aluminum salts in vaccines - US perspective [J].
Baylor, NW ;
Egan, W ;
Richman, P .
VACCINE, 2002, 20 :S18-S23
[6]  
Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
[7]   Cytokines, PGE2 and endotoxic fever:: a re-assessment [J].
Blatteis, CM ;
Li, SX ;
Li, ZH ;
Feleder, C ;
Perlik, V .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2005, 76 (1-4) :1-18
[8]   CONTACT SENSITIVITY TO ALUMINUM [J].
BOHLERSOMMEREGGER, K ;
LINDEMAYR, H .
CONTACT DERMATITIS, 1986, 15 (05) :278-281
[9]   Cytokines as adjuvants for the induction of mucosal immunity [J].
Boyaka, PN ;
McGhee, JR .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 51 (1-3) :71-79
[10]   Cognitive side-effects of adjuvant treatments [J].
Burstein, Harold J. .
BREAST, 2007, 16 :S166-S168